Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 90; no. 1; pp. 78 - 84
• Main Authors: Xia, Shu, Huang, Chiang-Ching, Le, Min, Dittmar, Rachel, Du, Meijun, Yuan, Tiezheng, Guo, Yongchen, Wang, Yuan, Wang, Xuexia, Tsai, Susan, Suster, Saul, Mackinnon, Alexander C., Wang, Liang
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.10.2015
• Subjects: Adenocarcinoma - blood; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Allele-specific PCR; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Case-Control Studies; cfDNA; Copy number variations; Digital PCR; DNA Copy Number Variations - genetics; DNA Mutational Analysis - instrumentation; DNA Mutational Analysis - methods; DNA, Neoplasm - blood; DNA, Neoplasm - genetics; Female; Genetic Variation; Hematology, Oncology and Palliative Medicine; High-Throughput Nucleotide Sequencing - methods; Humans; Lung Neoplasms - blood; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Middle Aged; Mutation; Neoplasm Staging; Next generation sequencing; Non-small cell lung cancer; Plasma; Plasma Cells - metabolism; Plasma Cells - pathology; Polymerase Chain Reaction - methods; Pulmonary/Respiratory; Plasma; Allele-specific PCR; Copy number variations; cfDNA; Non-small cell lung cancer; Digital PCR; Next generation sequencing

•Developed a novel plasma genomic abnormality (PGA) score for CNV analysis.•Demonstrated potential use of PGA scores in early detection of lung cancer.•Showed detectable gene mutations in early stage lung cancer. Cell free tumor DNA (cfDNA) circulating in blood has a great potential as biomarker for...